Long-term safety study of Riliprubart for CIDP
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CIDP and are currently taking riliprubart.
- You finished the main part of a prior riliprubart study (PDY16744, EFC17236, or EFC18156).
- You agree to use birth control during and after the study as needed.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have lupus or a known severe allergy to riliprubart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests a new medicine called paridiprubart to see if it can help people with moderate or severe acute respiratory distress syndrome (ARDS), a serious lung condition. It may be an option if you have low oxygen levels and no known allergy to the drug.
Hear when a new Polyneuropathy, Inflammatory Demyelinating, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.